Meeting
2013 ASCO Annual Meeting
A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).
Authors
Justin F. Gainor
Massachusetts General Hospital, Boston, MA
Justin F. Gainor , Anna M. Varghese , Sai-Hong Ignatius Ou , Sheheryar Kabraji , Mark M Awad , Ryohei Katayama , Amanda Pawlak , Mari Mino-Kenudson , Beow Y. Yeap , Gregory J. Riely , Anthony John Iafrate , Maria E. Arcila , Marc Ladanyi , Jeffrey A. Engelman , Dora Dias-Santagata , Alice Tsang Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8083)
DOI
10.1200/jco.2013.31.15_suppl.8083
Abstract #
8083
Poster Bd #
37G
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.
First Author: Marzia Del Re
Poster
2016 ASCO Annual Meeting
Molecular profile in non-small cell lung cancers (NSCLCs) occurring in elderly.
First Author: Caterina Fumagalli
Poster
2011 ASCO Annual Meeting
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.
First Author: J. Yang
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita